The estimated Net Worth of David C Hastings is at least $277 Tysiąc dollars as of 1 February 2024. David Hastings owns over 9,593 units of Scynexis Inc stock worth over $254,670 and over the last 21 years he sold SCYX stock worth over $22,160. In addition, he makes $0 as Director at Scynexis Inc.
David has made over 11 trades of the Scynexis Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 9,593 units of SCYX stock worth $22,160 on 1 February 2024.
The largest trade he's ever made was exercising 275,000 units of Scynexis Inc stock on 13 February 2014 worth over $3,575,000. On average, David trades about 17,186 units every 136 days since 2004. As of 1 February 2024 he still owns at least 181,907 units of Scynexis Inc stock.
You can see the complete history of David Hastings stock trades at the bottom of the page.
David Hastings is the Director at Scynexis Inc.
David's mailing address filed with the SEC is 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY, NJ, 07302-6548.
Over the last 11 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado oraz Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Scynexis Inc executives and other stock owners filed with the SEC include: